본문 바로가기
KERD
논문KCI 등재

Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori

황성규|홍성표|고광현|Kwang Ho Yoo|권창일|Won Hee Kim|Sang-Pil Yun|Han Gyung Seon|Chang Soo Ok|Min Kyung Kang|Pil Won Park
거트앤리버 소화기연관학회협의회|2012.10|Gut and Liver|제6권 제4호|pp. 452-456

1

조회

0

다운로드

3

인용

0

참고문헌

키워드

EradicationHelicobacter pyloriRifaximin

초록

Background/Aims: This study assessed the efficacy of a rifaximin plus levofloxacin-based rescue regimen in patients that had failed both triple and quadruple standard regimens for the eradication of Helicobacter pylori. Methods: We treated patients for H. pylori between August 2009 and April 2011. The triple regimen consisted of combined treatment with amoxicillin, clarithromycin, and pantoprazole for 1 week. For failed cases, a quadruple regimen of tetracycline, metronidazole, bismuth dicitrate, and lansoprazole for 1 week was administered. The rescue regimen for persistently refractory cases was rifaximin 200 mg t.i.d., levofloxacin 500 mg q.d., and lansoprazole 15 mg b.i.d. for 1 week. Results: In total, 482 patients were enrolled in this study. The eradication rates associated with the first and second regimens were 58% and 60%, respectively. Forty-seven out of 58 patients who failed with the second-line regimen received rifaximin plus levofloxacin-based third-line therapy. The eradication rate for the third regimen was 65%. The cumulative eradication rates were 58%, 85%, and 96% for each regimen, respectively. Conclusions: A rifaximin plus levofloxacin-based regimen could be an alternative rescue therapy in patients with resistance to both triple and quadruple regimens for the eradication of H. pylori.

Abstract

Background/Aims: This study assessed the efficacy of a rifaximin plus levofloxacin-based rescue regimen in patients that had failed both triple and quadruple standard regimens for the eradication of Helicobacter pylori. Methods: We treated patients for H. pylori between August 2009 and April 2011. The triple regimen consisted of combined treatment with amoxicillin, clarithromycin, and pantoprazole for 1 week. For failed cases, a quadruple regimen of tetracycline, metronidazole, bismuth dicitrate, and lansoprazole for 1 week was administered. The rescue regimen for persistently refractory cases was rifaximin 200 mg t.i.d., levofloxacin 500 mg q.d., and lansoprazole 15 mg b.i.d. for 1 week. Results: In total, 482 patients were enrolled in this study. The eradication rates associated with the first and second regimens were 58% and 60%, respectively. Forty-seven out of 58 patients who failed with the second-line regimen received rifaximin plus levofloxacin-based third-line therapy. The eradication rate for the third regimen was 65%. The cumulative eradication rates were 58%, 85%, and 96% for each regimen, respectively. Conclusions: A rifaximin plus levofloxacin-based regimen could be an alternative rescue therapy in patients with resistance to both triple and quadruple regimens for the eradication of H. pylori.

참고문헌 (44)

  1. Malfertheiner P, "Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report", Aliment Pharmacol Ther, 16, pp.167~180 (2002)
  2. Scarpignato C, "Towards the ideal regimen for Helicobacter pylori eradication: the search continues", Dig Liver Dis, 36, pp.243~247 (2004)
  3. Romano M, "Eradication of Helicobacter pylori: a clinical update", MedGenMed, 6, pp.19~ (2004)
  4. McLoughlin RM, "Eradication of Helicobacter pylori: recent advances in treatment", Fundam Clin Pharmacol, 19, pp.421~427 (2005)
  5. Candelli M, "Treatment of H. pylori infection: a review", Curr Med Chem, 12, pp.375~384 (2005)
  6. Ford AC, "Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis", Am J Gastroenterol, 99, pp.1833~1855 (2004)
  7. Pilotto A, "Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer", Dig Liver Dis, 32, pp.763~768 (2000)
  8. 조동근, "Helicobacter pylori 제균율 변화와일차 제균에 영향을 미치는 임상 인자", 대한소화기학회지, 55(6), pp.368~375 (2010), 대한소화기학회
  9. Zullo A, "High eradication rates of Helicobacter pylori with a new sequential treatment", Aliment Pharmacol Ther, 17, pp.719~726 (2003)
  10. Parente F, "Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts", Dig Liver Dis, 35, pp.523~528 (2003)
  11. Pilotto A, "In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin", Am J Gastroenterol, 95, pp.833~834 (2000)
  12. Heep M, "Rifampin and rifabutin resistance mechanism in Helicobacter pylori", Antimicrob Agents Chemother, 43, pp.1497~1499 (1999)
  13. Jiang ZD, "Rifaximin: in vitro and in vivo antibacterial activity: a review", Chemotherapy, 51(Suppl 1), pp.67~72 (2005)
  14. Gerard L, "Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections", Expert Rev Anti Infect Ther, 3, pp.201~211 (2005)
  15. Zullo A, "A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication", Dig Liver Dis, 35, pp.232~236 (2003)
  16. Gisbert JP, "Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures", Aliment Pharmacol Ther, 24, pp.1469~1474 (2006)
  17. 서검석, "Seroprevalence of Helicobacter pylori in South Korea", HELICOBACTER, 12, pp.333~340, BLACKWELL PUBLISHING
  18. 김승영, "국내 Helicobacter pylori 의 제균 치료", 대한소화기학회지, 58(2), pp.67~73 (2011), 대한소화기학회
  19. 김재연, "한국인의 위·십이지장 질환에 따른 Helicobacter pylori 균주의 일차 항생제 내성과 H. pylori 제균율", 대한소화기학회지, 58(2), pp.74~81 (2011), 대한소화기학회
  20. Hwang TJ, "Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea", J Clin Gastroenterol, 44, pp.536~543 (2010)
  21. Della Monica P, "Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy", Aliment Pharmacol Ther, 16, pp.1269~1275 (2002)
  22. Mesut Sezikli, "Effi cacy of the Combination of Tetracycline, Amoxicillin, and Lansoprazole in the Eradication of Helicobacter pylori in Treatment-Naïve Patients and in Patients Who Are Not Responsive to Clarithromycin-Based Regimens: A Pilot Study", Gut and Liver, 6(1), pp.41~44 (2012), 거트앤리버 발행위원회
  23. Gisbert JP, "‘Rescue’ therapy with rifabutin after multiple Helicobacter pylori treatment failures", Helicobacter, 8, pp.90~94 (2003)
  24. Perri F, "Rifabutin-based ‘rescue therapy’ for Helicobacter pylori infected patients after failure of standard regimens", Aliment Pharmacol Ther, 14, pp.311~316 (2000)
  25. Mégraud F, "In vitro activity of rifaximin against Helicobacter pylori", Eur J Clin Microbiol Infect Dis, 13, pp.184~186 (1994)
  26. Holton J, "The susceptibility of Helicobacter pylori to the rifamycin, rifaximin", J Antimicrob Chemother, 35, pp.545~549 (1995)
  27. Pretolani S, "Effect of rifaximin, a new non-absorbed antibiotic, in the treatment of Helicobacter pylori infection", Acta Gastroenterol Belg, 56, pp.144A~ (1993)
  28. Cammarota G, "Efficacy of two one-week rabeprazole", levofloxacin-based triple therapies for Helicobacter pylori infection, 2000, pp.14, 1339~1343
  29. Di Caro S, "Levofloxacin based regimens for the eradication of Helicobacter pylori", Eur J Gastroenterol Hepatol, 14, pp.1309~1312 (2002)
  30. Nista EC, "Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial", Aliment Pharmacol Ther, 18, pp.627~633 (2003)
  31. 이지현, "Helicobacter pylori 제균치료에서 Levofloxacin 병합요법의 효과", 대한소화기학회지, 48(1), pp.19~24 (2006), 대한소화기학회
  32. 정해선, "Helicobacter pylori 이차 제균에서 Levofloxacin 포함 삼제요법의 효과", 대한소화기학회지, 51(5), pp.285~290 (2008), 대한소화기학회
  33. Gasbarrini A, "Eradication of Helicobacter pylori: are rifaximin-based regimens effective?", Digestion, 73(Suppl 1), pp.129~135 (2006)
  34. Gasbarrini A, "Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study", Dig Dis, 24, pp.195~200 (2006)
  35. 송종규, "경기서부 단일기관에서 최근 11년간의 헬리코박터 파일로리 제균율 변화", 대한내과학회지, 76(3), pp.303~310 (2009), 대한내과학회
  36. 최유식, "Helicobacter pylori 일차 삼제 제균요법의 연도별 제균율 분석: 단일 기관의 최근 8년 성적", 대한소화기학회지, 48(3), pp.156~161 (2006), 대한소화기학회
  37. Chung JW, "The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea", Hepatogastroenterology, 58, pp.246~250 (2011)
  38. 정우철, "Helicobacter pylori 제균요법 적용의 실태 분석: 단일 기관 연구", 대한소화기학회지, 53(4), pp.221~227 (2009), 대한소화기학회
  39. 나현식, "Helicobacter pylori 일차 및 이차 치료의 제균율 변화와 재감염률", 대한소화기학회지, 50(3), pp.170~175 (2007), 대한소화기학회
  40. 조한진, "대구, 경북 지역 Helicobacter pylori 일차 및 이차 치료의 연도별 제균율 변화 : 최근 9년 성적", 대한내과학회지, 76(2), pp.186~192 (2009), 대한내과학회
  41. 오정환, "Helicobacter pylori 이차 사제 병합요법의 제균율", Clinical Endoscopy, 39(3), pp.131~135 (2009), 대한소화기내시경학회
  42. 조은주, "Helicobacter pylori 이차 사제요법의 제균율 변화 및 제균 성공에 영향을 미치는 요인", Clinical Endoscopy, 38(1), pp.14~19 (2009), 대한소화기내시경학회
  43. Malfertheiner P, "Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report", Gut, 56, pp.772~781 (2007)
  44. Lee SK, "Effectiveness and Safety of Repeated Quadruple Therapy in Helicobacter pylori Infection After Failure of Second-line Quadruple Therapy", HELICOBACTER, 16(5), pp.410~414, WILEY-BLACKWELL

관련 논문AI추천

Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication계세협, 김경호, 김동준, 김연수, 김진봉, 김학양, 박철희, 백광호, 백일현, 석기태, 신운건, 윤재훈, 장현주, Kyoung Oh Kim거트앤리버 소화기연관학회협의회 · Gut and Liver2012 · 제6권 제4호Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease김광하, 김상균, 김선문, 김재규, 김지현, 김태호, 김현수, 김흥업, 송지현, 신운건, 심기남, 이동호, 이중엽, 임주현, 전성우, 정일권, 한재필, 홍수진, 황재진거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제2호Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea김광하, 류동엽, 문지윤, 송근암, 송철수, 유현석, 이봉은, 정재훈, 정정임거트앤리버 소화기연관학회협의회 · Gut and Liver2013 · 제7권 제4호The Efficacy of Moxifloxacin-Containing Triple Therapy after Standard Triple, Sequential, or Concomitant Therapy Failure for Helicobacter pylori Eradication in Korea김나영, 김진욱, 서지연, 신철민, 이동호, 정광현, 정숙향, 조유리, 진은효, 황진혁거트앤리버 소화기연관학회협의회 · Gut and Liver2014 · 제8권 제6호Effi cacy of the Combination of Tetracycline, Amoxicillin, and Lansoprazole in the Eradication of Helicobacter pylori in Treatment-Naïve Patients and in Patients Who Are Not Responsive to Clarithromycin-Based Regimens: A Pilot StudyAtakan Yeşil, Ayşe Oya Övünç Kurdaş, Fatih Güzelbulut, Mesut Sezikli, Mustafa Erhan Altınöz, Nuriye Ulu, Züleyha Akkan Çetinkaya거트앤리버 소화기연관학회협의회 · Gut and Liver2012 · 제6권 제1호Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection김나영, 박영수, 송인성, 신철민, 이동호, 이승태, 임지현, 조현진거트앤리버 소화기연관학회협의회 · Gut and Liver2015 · 제9권 제4호

이 간행물의 다른 논문 (21건)

Endoscopic Ultrasound in Gastroenteropancreatic Neuroendocrine TumorsMichelle Kang Kimpp. 405-410Dietary Factors: Major Regulators of the Gut’s MicrobiotaVerena Wieser, Herbert Tilg, Alexander R. Moschenpp. 411-416Role of Janus Kinase/Signal Transducers and Activators of Transcription in the Pathogenesis of Pancreatitis and Pancreatic Cancer유지훈, 김혜영pp. 417-422Characteristics of Hemorrhagic Peptic Ulcers in Patients Receiving Antithrombotic/Nonsteroidal Antiinflammatory Drug TherapyTeppei Kabemura, Yasuaki Motomura, Hirotada Akiho, Eikichi Ihara, Haruei Ogino, Kana Kakigao, Kazuhiko Nakamura, Kazuya Akahoshi, Toshiaki Ochiai, Keishi Komori, Kazuhiro Haraguchi, Munehiro Tanaka, Norimoto Nakamura, Yoshimasa Tanaka, Ryoichi Takayanagi, Tetsuhide Ito, Yoshiharu Chijiiwa, Naohiko Haradapp. 423-426Adsorptive Granulocyte/Monocyte Apheresis for the Maintenance of Remission in Patients with Ulcerative Colitis: A Prospective Randomized, Double Blind, Sham-Controlled Clinical TrialTakayuki Matsumoto, Ken Fukunaga, Yoko Yokoyama, Koji Kamokozuru, Kazuko Nagaseru, Shiro Nakamura, Hiroto Miwapp. 427-433
원문 보기